New and Accurate Testing and Diagnosing for Lyme Disease
Just released, April 1, 2013,Pharmasan Labs, a partner company to NeuroScience, Inc., has launched iSpot Lyme™, a novel diagnostic tool for detecting the bacterial infection caused by Borrelia Burgdorferi, the causative agent of Lyme disease. The iSpot Lyme test represents a breakthrough in diagnostic accuracy, leading to faster diagnosis and treatment.
The evaluation for diagnosis currently recommended by the Centers for Disease Control is a two-tier test consisting of Enzyme-Linked Immunosorbent Spot (ELISA) and Western Blot (WB) that detects antibodies to B. Burgdorferi. But its sensitivity is low – only about 30% in early stages and 50% in late. This gap in sensitivity leaves undiagnosed and untreated thousands of the approximately 32,500 new patients each year, as well as countless others who may have previously received false-negative results.
iSpot Lyme is a highly sensitive T cell-based Lyme ELISpot assay validated for the diagnosis of Lyme. By measuring T cell activity, iSpot Lyme accurately detects Lyme in 84% of cases and avoids false positives in 94% of cases.